Multiple Sclerosis: all 3,524 studies

Page 32 of 36. Open to participants first (668), then studies with results posted, then the rest; newest registration first within each.

• Head Circumference Growth in Children Who Develop Multiple Sclerosis Later in LifeWithdrawnNCT01377805
• BRAVE-DREAMS (BRAin VEnous DRainage Exploited Against Multiple Sclerosis)CompletedNCT01371760Not applicable
• Cohort Study of Clinically Isolated Syndrome and Early Multiple SclerosisStatus unknownNCT01371071
• Avonex PEN Satisfaction and Patients Experience Clinical TrialCompletedNCT01366040
• PRISM Registry: Pseudobulbar Affect Registry SeriesCompletedNCT01366027
• Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis OpticaStatus unknownNCT01364246Phase 1/2
• Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple SclerosisCompletedNCT01359566Phase 3
• Vascular Fundus Changes in Patients With High Probability of Chronic Cerebrospinal Venous Insufficiency (CCSVI)CompletedNCT01356134
• Depression and Fatigue in MS Patients Treated With Betaferon.CompletedNCT01354665
• Colecalciferol as an Add-on Treatment to Interferon-beta-1b for Treatment of Multiple Sclerosis (MS)Status unknownNCT01339676Phase 4
• Supported Treadmill Training for Progressive Multiple SclerosisCompletedNCT01339234Not applicable
• Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple SclerosisWithdrawnNCT01337427Phase 3
• Psychometric Validation of Cognitive EndpointsCompletedNCT01335633
• Evaluating Alemtuzumab as a Treatment in Stabilizing Neurocognitive Function In Relapsing Remitting Multiple Sclerosis PatientsStatus unknownNCT01333358Phase 3
• Longitudinal Pharmacokinetic, Pharmacodynamic, Immunological, and BiochemicalCompletedNCT01330498
• Manganese-Enhanced Magnetic Resonance Imaging in Healthy Volunteers and People With Multiple SclerosisCompletedNCT01326715Phase 1
• A Study of ELND002 in Patients With Relapsing Forms of Multiple SclerosisTerminatedNCT01318421Phase 1
• Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT01310166Phase 4
• Advanced MRI Measures of Repair in Alemtuzumab Treated PatientsCompletedNCT01307332Phase 3
• Cyclic Oral Methylprednisolone Trial in Multiple SclerosisCompletedNCT01305837Phase 2
• Development and Evaluation of a Cognitive Rehabilitation Program for Persons With Multiple SclerosisStatus unknownNCT01303770Not applicable
• Nurse-Led Manualized Telephone Support InterventionCompletedNCT01302431Not applicable
• The Gilenya Pregnancy RegistryCompletedNCT01285479
• Long Term Study of Fingolimod in MS Patients From the FTY Clinical ProgramCompletedNCT01281657
• The Effect of Transcutaneous Electrical Nerve Stimulation (TENS) in Multiple SclerosisCompletedNCT01280539Not applicable
• Melatonin in Relapsing-Remitting Multiple Sclerosis PatientsCompletedNCT01279876Phase 2
• Motor Training and White Matter in Multiple Sclerosis (MS)TerminatedNCT01279655Not applicable
• Visual Reconstitution Therapy After Optic NeuritisCompletedNCT01274702Phase 2
• Evaluation of Sloan-Charts for Assessment of Disease Progress in Multiple SclerosisCompletedNCT01272596
• Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - The AVAIL StudyCompletedNCT01272128
• Prevalence of Fabry Disease in a Defined Population at Risk - Patients Formerly Diagnosed With Multiple SclerosisCompletedNCT01271699
• Endovascular Treatment for Chronic Cerebrospinal Venous Insufficiency (CCSVI)CompletedNCT01264848Phase 1/2
• Vitamin D Pilot Study in Patients With Multiple SclerosisCompletedNCT01257958Phase 1
• Neurocognitive Changes in Patients With Remitting Relapsing Multiple Sclerosis Treated With NatalizumabStatus unknownNCT01250678
• Study Comparing Corpus Callosum Atrophy as a Marker of Later Development of Cognitive Impairment in Patients With Multiple SclerosisStatus unknownNCT01250665
• Safety Study of BIIB033 in Subjects With Multiple SclerosisCompletedNCT01244139Phase 1
• Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectorsCompletedNCT01235455
• Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.CompletedNCT01235221Phase 3
• BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus ProgramCompletedNCT01233245
• AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple SclerosisStatus unknownNCT01228396Phase 2
• Mesenchymal Stem Cell Transplantation in MSTerminatedNCT01228266Phase 2
• Quantitative Imaging and Proton Spectroscopy in Multiple SclerosisTerminatedNCT01226654Not applicable
• Cytotron® Delivered Rotational Field Quantum Nuclear Magnetic Resonance Therapy for Multiple SclerosisStatus unknownNCT01220830Phase 2
• Exercise as a Strategy to Treat Cognitive Dysfunction in Persons With Multiple SclerosisCompletedNCT01219647Phase 1/2
• Effects of Vestibular Rehabilitation on MS-related Fatigue: a Randomized Control TrialCompletedNCT01216137Not applicable
• Randomised Controlled Clinical Trial of Cognitive Rehabilitation in Multiple SclerosisCompletedNCT01207856Not applicable
• Applications of Nanotechnology in Multiple Sclerosis by Respiratory SamplesCompletedNCT01206023
• Evaluation of Angioplasty in the Treatment of Chronic Cerebrospinal Venous Insufficiency (CCSVI) in Multiple SclerosisTerminatedNCT01201707Not applicable
• Study of the Safety and Efficacy of MLN1202 in Patients in Multiple SclerosisCompletedNCT01199640Phase 2
• Assessment of Patient Use of a New Device: RebiSmartCompletedNCT01195870
• Assessment of Subject Use of the Rebiject II Injection Device According to Nurse Examination of Subject Accuracy in 10 Steps as a Dummy DemonstrationCompletedNCT01195857
• Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple SclerosisCompletedNCT01191996Phase 1/2
• JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)CompletedNCT01185717
• Evaluation of Risk Factors for Early Termination of Injection Treatment With Betaferon in Patients Suffering From Multiple SclerosisCompletedNCT01184833
• Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS)CompletedNCT01181115Phase 3
• Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)WithdrawnNCT01181089Phase 1/2
• REsPonse to Interferon-Alpha in InterfeRon-β Neutralizing Antibody Positive Multiple Sclerosis PatientsCompletedNCT01171209Phase 2
• Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple SclerosisCompletedNCT01158183
• Early Cognitive Impairment in Multiple SclerosisCompletedNCT01157728
• Controlled High Risk AVONEX® Multiple Sclerosis Prevention Study In Ongoing Neurological SurveillanceTerminatedNCT01156298
• Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple SclerosisCompletedNCT01149525Phase 3
• A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple SclerosisTerminatedNCT01144351Phase 1
• The Effects of Erythropoietin on Clinical Disability and Brain Pathology in Patients With Progressive Multiple SclerosisStatus unknownNCT01144117Phase 2
• Investigating Mechanism of Action of DAC HYP in the Treatment of High-Inflammatory Multiple Sclerosis (MS)CompletedNCT01143441Phase 1
• A Canadian Study Assessing the Utility of the Treatment Optimization Recommendations in Multiple SclerosisCompletedNCT01142583
• An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple SclerosisCompletedNCT01142557
• An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With MitoxantroneCompletedNCT01142518
• A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®)CompletedNCT01142492
• An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) PatientsCompletedNCT01142453
• An Observational Study Comparing Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) and Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) in Relapsing Multiple Sclerosis (RMS) Patients on Long-term Rebif® TherapyCompletedNCT01141751
• Treatment Adherence When Using RebiSmart™ in Relapsing Multiple Sclerosis SubjectsCompletedNCT01128075
• Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) PatientsCompletedNCT01127750Phase 3
• A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) SubjectsCompletedNCT01125475
• Effect of Aerobic Exercise on Side Effects of Disease Modifying Therapy With Subcutaneous Interferon-b1b in Patients With Multiple SclerosisCompletedNCT01122056Not applicable
• Pharmacogenomics of Drug Safety in Multiple SclerosisCompletedNCT01118130
• An Observational Study on the Progression of Clinically Isolated Syndrome to Multiple Sclerosis Over a 2-year PeriodCompletedNCT01112657
• An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These ParametersCompletedNCT01112345
• Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1bCompletedNCT01111656Phase 2
• A Prospective Study of Spasticity in Individuals With Multiple SclerosisStatus unknownNCT01111435
• An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF)CompletedNCT01110993
• An Observational Study for the Assessment of Adherence, Effectiveness and Convenience of Rebif® Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmart™.CompletedNCT01108887
• Repetitive Deep Transcranial Magnetic Stimulation in Multiple SclerosisCompletedNCT01106365Not applicable
• Hydroxyurea in Primary Progressive Multiple SclerosisTerminatedNCT01103583Phase 2/3
• Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.CompletedNCT01101776
• Autologous Stem Cell Transplant for Multiple SclerosisCompletedNCT01099930Phase 2
• Study of Alternative Exercise Therapies for Progressive Multiple Sclerosis (MS)CompletedNCT01097538Not applicable
• Study To Evaluate Treating Chronic Cerebrospinal Venous Insufficiency (CCSVI) in Multiple Sclerosis PatientsTerminatedNCT01089686Not applicable
• Rhythmic Auditory Stimulation and Walking Performance in Multiple Sclerosis (MS) PatientsWithdrawnNCT01086371Phase 2
• A Retrospective Study to Understand the Clinical Management of Subjects With Multiple Sclerosis at a Site in Taiwan Over the Last 10 YearsCompletedNCT01084798
• A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple SclerosisCompletedNCT01081782Phase 2
• Improving Hand Use in Multiple SclerosisStatus unknownNCT01081275Phase 2
• Rebif Compliance Support Program - Assessing Needs in Multiple SclerosisCompletedNCT01080573
• Sexual Dysfunction, Disability and Quality of Life in Patients With Multiple Sclerosis (MS)CompletedNCT01080053
• To Assess the Prevalence of Spasticity and the Impact on the Quality of Life in Multiple Sclerosis PatientsCompletedNCT01080040
• Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)CompletedNCT01080027
• Correlation Between Multiple Sclerosis Functional Composite (MSFC) and Expanded Disability Status Scale (EDSS) in Patients With Multiple Sclerosis (MS) in ArgentinaCompletedNCT01080014
• A Observational, Prospective Study to Assess the Impact of Fatigue in the Quality of Life of Patients With Multiple Sclerosis in ArgentinaCompletedNCT01080001
• To Identify and Evaluate the Predictive Factors for Depression in Patients Diagnosed With Multiple SclerosisCompletedNCT01079975
• Natalizumab Treatment of Progressive Multiple SclerosisCompletedNCT01077466Phase 2
• Prospective, Multicenter Non Interventional Study to Evaluate Adherence to Betaferon Over a 2 Years PeriodCompletedNCT01076595

← Multiple Sclerosis overview